Answers are grounded in this paper and cite their sources.
Our real-world analysis confirms the safety and efficacy profiles of T-DXd in patients with ABC. Prior immunotherapy and smoking emerged as risk factors for ILD, and NLR for neutropenia grade ≥3, and merit further investigation.
No takes yet. Share an insight, caveat, or question.
Antonarelli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: